International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
By D. Wingerchuk, B. Banwell, J. Bennett, P. Cabre, W. Carroll, T. Chitnis, J. de Seze, K. Fujihara, B. Greenberg, A. Jacob and 9 more. Neurology, 2015
3,748 citations recorded by the source corpus.
Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord involvement but more restricted or more extensive CNS involvement may occur. The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and electronic surveys to facilitate consensus. The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG). The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations. More stringent clinical criteria, with additional neuroimaging findings, are required for diagnosis of NMOSD without AQP4-IgG or when serologic testing is unavailable. The IPND also proposed validation strategies and achieved consensus on pediatric NMOSD diagnosis and the concepts of monophasic NMOSD and opticospinal MS.
Subfields: Neurology, Pathology and Forensic Medicine, Rheumatology
View Paper: https://www.semanticscholar.org/paper/779614566ed333701c55d2acbdffee32253e2297
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Neurology
In Pathology and Forensic Medicine
Citations in the corpus
- Clinical presentation and prognosis in MOG-antibody disease: a UK study (2017, background): “…47 fulfilled either the NMO 2006 (Wingerchuk et al., 2006) or NMOSD 2007 (Wingerchuk et al., 2007) criteria but only 17 fulfilled the NMOSD 2015 (Wingerchuk et al., 2015) criteria (because of the requirement for more than one area to be involved if AQP4 antibody-negative), two of whom fulfilled…”
- MOG encephalomyelitis: international recommendations on diagnosis and antibody testing (2018, background): “[30] will meet also the criteria for MOG-IgG testing given in Table 1 and should thus be tested.”
- MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome (2016, methodology): “%) patients met the 2015 international consensus criteria for NMOSD [29] (Table 1).”